Ulixertinib (BVD-523)
Histiocytosis & MAPK pathway-driven cancers
Phase 2Active
Key Facts
Indication
Histiocytosis & MAPK pathway-driven cancers
Phase
Phase 2
Status
Active
Company
About BioMed Valley Discoveries
BioMed Valley Discoveries is a privately held, clinical-stage biotech with a novel operational and funding structure, wholly owned by a supporting organization of the non-profit Stowers Institute for Medical Research. This setup provides stable capital, allowing the company to pursue risk-tolerant, early-stage translational and clinical programs in oncology and other serious diseases. Its most advanced candidate is ulixertinib, a first-in-class ERK1/2 inhibitor, with a Phase 2 trial ongoing in histiocytosis and other MAPK-driven cancers. The company's strategy is to de-risk assets through clinical proof-of-concept and then partner them for later-stage development and commercialization.
View full company profile